CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 90 enrolled
Drug / intervention
Probiotic +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06491342
NCT06491342N/ACompleted
CompareCT.gov

PROBIOTIC SUPPLEMENT VERSUS PLACEBO FOR DECREASE STEATOSIS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Phramongkutklao College of Medicine and Hospital·interventional·Posted Jul 9, 2024·Updated Jul 25, 2025

In Brief

A clinical study evaluating Probiotic and Placebo for Fatty Liver, Nonalcoholic. Completed, enrolled 90 participants across 2 sites.

Detailed Summary

Probiotic supplement versus placebo for the treatment of patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFatty Liver, Nonalcoholic
CountriesThailand
CollaboratorsChiang Mai University, Thailand Institute of scientific and technological research

Timeline

N/ACompletedFinished
20252026
First PostedJul 9, 2024
Enrollment StartJul 25, 2024
Primary CompletionApr 22, 2025
Study CompletionMay 28, 2025
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 2.0 years ago

Interventions

Probioticdietary

Probiotic-Lactobacillus Zeae and Lactobacillus reuteri

Placebodietary

placebo